Literature DB >> 16764747

Subacute cerebellar degeneration as paraneoplastic syndrome: initial symptom of breast cancer with HER2 overexpression.

M Isabel Gallegos Sancho1, M Reboredo Lopez, L Calvo Martinez, R Garcia Campelo, M S Lopez Facal, B Sanroman Budino, M Quindos Varela, S Antolin Novoa, M Valladares Ayerbes, G Alonso Curbera, L M Anton Aparicio.   

Abstract

We report the case of a patient with subacute cerebellar degeneration presenting as paraneoplastic syndrome, preceding the final diagnosis of breast cancer. The tumor had high HER2 overexpression, so a weekly regimen of paclitaxel/trastuzumab was started after surgery of the primary breast tumor. Negativity of specific antineuronal antibodies and clinical stabilization of the patient was achieved after 12 cycles of treatment. The interest of this case is the unusual presentation and the targeted therapeutic approach that has been used.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16764747     DOI: 10.3816/cbc.2006.n.016

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  4 in total

Review 1.  Anti-Yo antibody-mediated paraneoplastic cerebellar degeneration associated with cognitive affective syndrome in a patient with breast cancer: a case report and literature review.

Authors:  M Le May; S Dent
Journal:  Curr Oncol       Date:  2018-12-01       Impact factor: 3.677

2.  Paraneoplastic Encephalitis Associated with Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer.

Authors:  Rebecca C Shay; Jennifer R Diamond; Jodi A Kagihara; Sharon B Sams
Journal:  J Breast Cancer       Date:  2021-02       Impact factor: 3.588

3.  Paraneoplastic cerebellar degeneration diagnosed by anti-Yo determination in a young woman with early breast cancer.

Authors:  Oriol Mirallas; María Alejandra Rezqallah Arón; Nadia Saoudi Gonzalez; Santiago Escrivá-de-Romaní
Journal:  BMJ Case Rep       Date:  2020-08-24

Review 4.  Paraneoplastic cerebellar degeneration with anti-Yo antibodies - a review.

Authors:  Anand Venkatraman; Puneet Opal
Journal:  Ann Clin Transl Neurol       Date:  2016-06-30       Impact factor: 4.511

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.